Nagoya protocol

Search Imperial Search Section Navigation • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • The Nagoya Protocol on Access to Genetic Resources and the Fair and Equitable Sharing of Benefits Arising from their Utilization to the Convention on Biological Diversity (the Protocol) aims to ensure that owners or guardians of genetic resources receive a “fair share” of any benefits that arise from research conducted with those resources. The Nagoya Protocol came into force on 12 October 2014, and has been signed by over 50 countries including the UK and the EU. The protocol applies to genetic resources, traditional knowledge associated with genetic resources; and the benefits arising from the utilization of such genetic resources and associated traditional knowledge. It also applies to any organismal research or collection storing organismal life. It covers research disciplines indirectly linked to biosciences, such as earth or climate science (GR in drill cores, water, or soil samples) and archaeological sciences (archaeobotany, archaeozoology, and archaeology), and, could apply if these samples are used for...

Michael Heinrich 1*, Francesca Scotti 1, Adolfo Andrade-Cetto 2†, Monica Berger-Gonzalez 3, Javier Echeverría 4†, Fabio Friso 5, Felipe Garcia-Cardona 6†, Alan Hesketh 7†, Martin Hitziger 8†, Caroline Maake 9†, Matteo Politi 5,10†, Carmenza Spadafora 11 and Rita Spadafora 12 • 1Research Group ‘Pharmacognosy and Phytotherapy’, UCL School of Pharmacy, University of London, London, United Kingdom • 2Laboratorio de Etnofarmacología, Facultad de Ciencias, Universidad Nacional Autónoma de México, Mexico City, Mexico • 3Centro de Estudios en Salud, Universidad del Valle de Guatemala, Guatemala City, Guatemala • 4Departamento de Ciencias del Ambiente, Facultad de Química y Biología, Universidad de Santiago de Chile, Santiago, Chile • 5Departmento de Investigación, Centro de Rehabilitación de Toxicómanos y de Investigación de Medicinas Tradicionales-Takiwasi, Tarapoto, Peru • 6Instituto de Investigación de Recursos Biológicos, Alexander von Humboldt, Sede Venado del Oro, Bogotá, Colombia • 7Indigena Biodiversity Limited, Gerrards Cross, United Kingdom • 8Section of Epidemiology, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland • 9Institute of Anatomy, University of Zurich, Zurich, Switzerland • 10Department of Pharmacy, University of Chieti-Pescara, Chieti Scalo, Italy • 11Centro de Biología Celular y Molecular de Enfermedades (CBCMe), Instituto de Investigaciones Científicas y Servicios de Alta Tecnología (INDICASAT AIP), Panama City, Panamá • 12Asociación Nacional de ...

• Home • About • About the Nagoya Protocol • How is this site for you? • About the Site • Guides • All • Detailed Guide to The Nagoya Protocol • Guide to Nagoya Terminology • Guide to ABS Clearinghouse • Guide to Benefit Sharing • Guide to Submitting a Use Case or Story • Use Cases • Use Cases & Stories • By Country • Resources • Workshop Series • Further Reading • Media • Ask the Community • The ‘Nagoya Protocol on Access to Genetic Resources and the Fair and Equitable Sharing of Benefits Arising from their Utilization’ started as a concept that arose from the The Nagoya Protocol is a multilateral treaty that sets up a legal framework for utilizing genetic resources. A genetic resource is a physical object of biological origin and the intellectual information associated with it such as traditional knowledge. They have actual or potential value and contain functional units of heredity that can be explored through research and exploited in development. The Nagoya Protocol has broad applicability to guide how we do international research, plan future collections of biological materials and information, and manage collections and documents from the past. Neither the Nagoya Protocol nor the CBD are intended to slow or prevent research. These efforts are to help facilitate fair and equitable benefit from activities such as research, in the global interest of having more capacity to understand and protect biodiversity, which we are losing at an alarming rate. The Nagoya Protocol...

• Replacement of CELEX identifiers by short titles - experimental feature. It replaces clickable CELEX identifiers of treaties and case-law by short titles. • Visualisation of document relationships. It displays a dynamic graph with relations between the act and related documents. It is currently only available for legal acts. • Deep linking. It enables links to other legal acts referred to within the documents. It is currently only available for documents smaller than 900 KB. ​ Regulation (EU) No 511/2014 of the European Parliament and of the Council of 16 April 2014 on compliance measures for users from the Nagoya Protocol on Access to Genetic Resources and the Fair and Equitable Sharing of Benefits Arising from their Utilization in the Union Text with EEA relevance Regulation (EU) No 511/2014 of the European Parliament and of the Council of 16 April 2014 on compliance measures for users from the Nagoya Protocol on Access to Genetic Resources and the Fair and Equitable Sharing of Benefits Arising from their Utilization in the Union Text with EEA relevance Regulation (EU) No 511/2014 of the European Parliament and of the Council of 16 April 2014 on compliance measures for users from the Nagoya Protocol on Access to Genetic Resources and the Fair and Equitable Sharing of Benefits Arising from their Utilization in the Union Text with EEA relevance OJ L 150, 20.5.2014, p. 59–71 (BG, ES, CS, DA, DE, ET, EL, EN, FR, GA, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV) I...

Overview The Nagoya Protocol is a multilateral treaty addressing access and benefit-sharing. For the countries that have become party, itgoverns the international sharing of genetic resources. Implementation of this treaty has implications for public health including, in particular, aspects of a timely response to infectious disease outbreaks. WHO – in close collaboration with the Convention on Biological Diversity, Member States and other international organizations and stakeholders – is working to ensure that public health work advances in harmony with the implementation of the Nagoya Protocol. This page contains information on WHO’s ongoing efforts in regard to the implementation of decision WHA72(13) on the public health implications of implementation of the Nagoya Protocol. In collaboration with the Secretariat of the Convention on Biological Diversity in the implementation of decision WHA72(13), the WHO Secretariat developed a survey to collect information requested from stakeholders concerned by the public health implications of the Nagoya Protocol. Results will be made available to the WHA submitted through the 148th session of the Executive Board in January 2021. At the 138th Executive Board, it was agreed that the Secretariat would prepare a study, for presentation to the Board at its 140th session, to analyze how the implementation of the Nagoya Protocol might affect the sharing of pathogens, and the potential public health implications. The study is available i...

• Areas of work • • • • • • • • • • • • • • • • • • • • • • • • • • Initiatives • • Flagship initiatives • Partnerships and alliances • Industry roundtables • #AlwaysInnovating: The pharmaceutical innovation journey • Global Health Progress • The COVID-19 Innovation Timeline • News and resources • News • Press releases • Statements • Publications • Reports • Position papers • External studies • Resources • Infographics • Videos • Toolkits • Expert insights • Press briefings • Events • About us • Our Experts • Secretariat • Governance and leadership • • • Companies • Associations • Affiliates • When it comes to global public health and health security, it’s essential that researchers can share information about dangerous viruses, bacteria, and other pathogens as rapidly as possible. One of the biggest lessons learned from COVID-19 is that no response is possible without access to pathogen samples and information. Without these, innovation can’t begin. The innovative pharmaceutical industry actively highlights the consequences of restricting the sharing of pathogens and their information to global health security. To help raise awareness of the importance of pathogen sharing for public health, IFPMA takes part in formal meetings of the UN Convention on Biological Diversity, including the Nagoya Protocol. We also offer our practical, firsthand insight into the realities of pathogen sharing and how this is seriously impacted by rules made to protect biodiversity. The need for ...